Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib adjuvant therapy for resected NSCLC with rare EGFR mutations
CTR20222425Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Feb 2023; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20222425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222425.